AbbVie on Friday said the deal adds Nimble's lead asset, an investigational oral peptide in preclinical development for the treatment of psoriasis, and a pipeline of other candidates with potential ...

intellectual stimulating work of diagnosing and treating diseases, being involved in medical research.” But three years ago, ...